AI Tool Comparison

Comparing as AI Medical Research & Clinical Decision Support
Atomwise vs BenevolentAI

Atomwise

Enterprise

Visit Website Full Review

BenevolentAI

Enterprise

Visit Website Full Review

Verdict by Category

Detailed category analysis is not available for this comparison.

View Atomwise View BenevolentAI

Feature & Spec Matrix

Detailed Comparison22 Criteria

Complete side-by-side breakdown of specifications, capabilities, and feature parity

Swipe horizontally to compare features

Feature / Spec

Atomwise

BenevolentAI

Pricing Model

EnterpriseAtomwise operates through enterprise partnership and co-development agreements — there is no self-serve access or published pricing. Collaboration types include: sponsored research agreements (pharma/biotech pays Atomwise to run AI-powered hit discovery campaigns), co-development partnerships (shared IP and milestone/royalty structures), and academic program access for universities through the ATOM initiative. New CEO Steve Worland is also steering Atomwise toward an internal proprietary drug pipeline, which will generate revenue through future licensing and partnering deals as candidates mature into preclinical and clinical stages. Contact Atomwise through atomwise.com for partnership and collaboration inquiries.

EnterpriseBenevolentAI operates through enterprise pharma collaboration agreements and platform licensing — there is no self-serve access or published pricing. Revenue models include: discovery collaborations with pharma companies (AstraZeneca, Merck) structured as multi-year agreements with upfront fees and milestones; licensing of its knowledge exploration tools as standalone software to pharma R&D organizations; and advancing its own clinical pipeline to inflection points for licensing or co-development. Total funding raised is approximately $1.9B, with the company listed on Euronext Amsterdam (AMS: BAI). Contact BenevolentAI through benevolent.com for partnership and platform licensing inquiries.

Starting Price

Custom / Contact Sales

Free Plan & Trial Scope

Difference

No free plan — enterprise and academic collaboration agreements via sales/partnership team

No free access — enterprise pharma partnerships and platform licensing via sales team

User Rating Score

Unrated

Ideal Workflow / Use Case

Difference

Pharmaceutical and biotech R&D teams needing AI-powered virtual screening and hit discovery against novel, difficult, or undruggable disease targets at industrial scale

Pharmaceutical companies and researchers needing AI-powered knowledge mining for novel drug target identification and disease hypothesis generation in complex diseases

Enterprise & Scalability

Difference

Enterprise pharma collaboration agreements; 250+ partner network; custom research contracts with major pharmaceutical, agrochemical, and biotech companies; academic partnership program for universities including Harvard, Stanford, and Duke

Euronext Amsterdam listed (AMS: BAI), $1.9B total raised, in-house wet lab facilities in Cambridge UK, strategic collaborations with AstraZeneca and Merck, HIPAA/GDPR compliant data practices, enterprise licensing for knowledge exploration tools

Core Categories

AI Healthcare ToolsAI Research & Education Tools

AtomNet — world's first deep CNN for structure-based drug discovery, screening 16B+ compounds in under 2 days

Supported

600+ unique disease targets tackled across oncology, CNS, infectious disease, and rare diseases

Supported

185+ completed projects validated across diverse protein types including undruggable targets

Difference

Atomwise Advantage

Not listed

775+ collaborations with 250+ partners worldwide — pharma, biotech, agrochemical, and academic

Supported

Foundation Model for molecular discovery — next-generation AI announced at TRANSONC 2026

Difference

Atomwise Advantage

Not listed

Proprietary pipeline of small-molecule drug candidates advancing into preclinical studies

Supported

AIDDISON platform for structure-based hit discovery and lead optimization

Difference

Atomwise Advantage

Not listed

Co-development agreements with major pharma — Merck, and 4 of top 10 US pharmaceutical companies

Difference

Atomwise Advantage

Not listed

Academic ATOM program: collaborations with 40+ universities including Harvard, Stanford, and Duke

Difference

Atomwise Advantage

Not listed

Founded 2012 — pioneered deep learning in drug discovery; $226M+ total raised

Supported

Benevolent Platform — AI knowledge graph integrating scientific literature, databases, and experimental data

Difference

Not listed

BenevolentAI Advantage

Target identification and disease hypothesis generation from multimodal biomedical data

Difference

Not listed

BenevolentAI Advantage

In-house wet lab facilities in Cambridge UK for AI hypothesis validation

Difference

Not listed

BenevolentAI Advantage

Integrated AI + wet lab model: AI generates hypotheses, scientists validate in physical experiments

Difference

Not listed

BenevolentAI Advantage

Offices in London HQ, Cambridge wet labs, and New York

Difference

Not listed

BenevolentAI Advantage

Atomwise Pros & Cons

Pros

Invented deep learning for structure-based drug discovery in 2012 — true pioneer in the field
AtomNet screens 16B+ compounds in under 2 days — fastest virtual screening at this scale
775+ collaborations and 250+ partners — most validated partnership network in AI drug discovery
Tackles undruggable targets that traditional methods can't address
Strong academic program: 40+ universities including Harvard, Stanford, and Duke
New Foundation Model announced 2026 — next-generation AI for molecular discovery
$226M+ raised from DCVC, Khosla, Y Combinator, Tencent, B Capital, and Baidu

Cons

Early-stage company — no FDA-approved drugs from the platform yet
Shifting focus from platform licensing to proprietary pipeline adds execution risk
Smaller team (~100-250 employees) compared to larger AI drug discovery peers
Revenue still modest at $5-25M range — pre-commercial stage
Deep tech focus means long timelines before patient impact is realized

BenevolentAI Pros & Cons

Pros

Fully integrated AI + wet lab model — unique among AI drug discovery platforms
AstraZeneca and Merck partnerships validate the platform's target identification quality
In-house wet labs in Cambridge close the loop between AI prediction and biology
Euronext Amsterdam listed (AMS: BAI) — $1.9B raised, publicly accountable
Phase 1 clinical data for BEN-8744 (ulcerative colitis) represents real clinical progress
Multiple disease areas covered: oncology, rare disease, CNS, fibrosis, and immunology
Knowledge exploration tools can be licensed separately from drug pipeline

Cons

Listed on Euronext Amsterdam (AMS: BAI) — less accessible to US retail investors
Clinical pipeline still in early stages — no approved drugs yet
Smaller than competitors like Recursion in terms of funding and team size
Revenue dependent on collaboration milestones — lumpy and uncertain
Wet-lab operations add cost complexity vs. pure software drug discovery peers

Head-to-Head Battle Cards